These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34568454)

  • 41. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.
    Agid O; Schulze L; Arenovich T; Sajeev G; McDonald K; Foussias G; Fervaha G; Remington G
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1017-22. PubMed ID: 23706529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Neuropsychopharmacology; 2004 Dec; 29(12):2200-7. PubMed ID: 15328528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.
    Chen CH; Shyue SK; Hsu CP; Lee TS
    Cell Physiol Biochem; 2018; 50(4):1216-1229. PubMed ID: 30355932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.
    Jeste DV; Barak Y; Madhusoodanan S; Grossman F; Gharabawi G
    Am J Geriatr Psychiatry; 2003; 11(6):638-47. PubMed ID: 14609804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do antipsychotic drugs increase seizure frequency in epilepsy patients?
    Okazaki M; Adachi N; Akanuma N; Hara K; Ito M; Kato M; Onuma T
    Eur Neuropsychopharmacol; 2014 Nov; 24(11):1738-44. PubMed ID: 25453222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
    Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
    J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Eur J Clin Pharmacol; 2001 Jul; 57(4):327-31. PubMed ID: 11549212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.
    Szota AM; Araszkiewicz AS
    Int Clin Psychopharmacol; 2019 Jan; 34(1):1-8. PubMed ID: 30398998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognitive effects of olanzapine treatment in schizophrenia.
    McGurk SR; Lee MA; Jayathilake K; Meltzer HY
    MedGenMed; 2004 May; 6(2):27. PubMed ID: 15266253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
    Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN
    CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.
    Kinon BJ; Ahl J; Rotelli MD; McMullen E
    Am J Emerg Med; 2004 May; 22(3):181-6. PubMed ID: 15138953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.
    Maffioletti E; Valsecchi P; Minelli A; Magri C; Bonvicini C; Barlati S; Sacchetti E; Vita A; Gennarelli M
    Drug Dev Res; 2020 Sep; 81(6):754-761. PubMed ID: 32462699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
    Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
    Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs.
    Atkins JB; Chlan-Fourney J; Nye HE; Hiroi N; Carlezon WA; Nestler EJ
    Synapse; 1999 Aug; 33(2):118-28. PubMed ID: 10400890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.